| Not Yet Recruiting | 18F-PSMA PET/CT Versus CT Alone in Assessment of Prostatic Cancer Patients NCT07485881 | Assiut University | — |
| Recruiting | Geriatric Assessment and Technology Evaluation in Prostate Cancer NCT06215508 | University of Chicago | — |
| Recruiting | A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic NCT07292168 | Kidney Cancer Research Bureau | Phase 1 / Phase 2 |
| Recruiting | A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With NCT07255664 | Curacell Holding AB | Phase 1 / Phase 2 |
| Recruiting | Exercise in Prostate Cancer NCT06165302 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Suspended | Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer NCT05361915 | Sorrento Therapeutics, Inc. | Phase 2 |
| Recruiting | Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Alg NCT07484971 | Société Algérienne de Formation et Recherche en Oncologie | — |
| Recruiting | Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 NCT06972628 | Ebrahim S Delpassand | Phase 2 |
| Recruiting | PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN) NCT07089550 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Recruiting | Dynamic 68Ga-PSMA and 18F-FDG PET/CT Analysis Prior to 177Lu-PSMA NCT06450548 | Centre Henri Becquerel | N/A |
| Recruiting | Castrate Resistant Prostate Cancer Enhertu Therapy NCT06610825 | Washington D.C. Veterans Affairs Medical Center | Phase 2 |
| Completed | Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration- NCT06461689 | Central Hospital, Nancy, France | — |
| Not Yet Recruiting | The Diagnostic Value of FAPI PET/CT in Staging of Newly Diagnosed Prostate Cancer NCT06634173 | The Netherlands Cancer Institute | N/A |
| Recruiting | Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders) NCT06496581 | UNICANCER | Phase 3 |
| Recruiting | A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer NCT06320067 | University College, London | Phase 3 |
| Not Yet Recruiting | Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Stu NCT06430411 | Medical University of Vienna | — |
| Recruiting | ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical NCT06141993 | Duke University | — |
| Recruiting | Clinical Application of the J-PET Scanner Prototype NCT06242119 | Jagiellonian University | — |
| Recruiting | Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics NCT06260410 | Erasmus Medical Center | — |
| Unknown | Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) NCT06251492 | Fudan University | Phase 2 |
| Enrolling By Invitation | 177Lu-HTK03170 in mCRPC With PSMA Positive Disease NCT05570994 | British Columbia Cancer Agency | Phase 1 / Phase 2 |
| Recruiting | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) NCT06136624 | Merck Sharp & Dohme LLC | Phase 3 |
| Withdrawn | ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer NCT05567770 | Weill Medical College of Cornell University | Phase 1 |
| Recruiting | Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer NCT06171139 | University of California, San Francisco | N/A |
| Withdrawn | Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients NCT05156372 | The University of Texas Health Science Center at San Antonio | N/A |
| Terminated | HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer NCT05553639 | Hookipa Biotech GmbH | Phase 1 / Phase 2 |
| Recruiting | Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAP NCT05563558 | Fundacion Oncosur | Phase 2 |
| Recruiting | FTT PET/CT in Metastatic Prostate Cancer NCT05242744 | Abramson Cancer Center at Penn Medicine | — |
| Terminated | A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Canc NCT05679388 | University of Chicago | Phase 1 |
| Terminated | Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. NCT05276492 | University of Chicago | Phase 1 |
| Unknown | BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC NCT05530395 | Ignacio Puche Sanz | — |
| Recruiting | Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate) NCT05457699 | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 2 |
| Recruiting | Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Thera NCT05327465 | Dana-Farber Cancer Institute | N/A |
| Recruiting | Metastasis-directed Therapy for Oligorecurrent Prostate Cancer NCT05352178 | Universitaire Ziekenhuizen KU Leuven | Phase 3 |
| Recruiting | ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6 NCT04916613 | UNICANCER | Phase 3 |
| Completed | Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) NCT05177042 | Arvinas Androgen Receptor, Inc. | Phase 1 |
| Unknown | 68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis NCT05627778 | Peking Union Medical College Hospital | Phase 1 / Phase 2 |
| Recruiting | Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer NCT04983095 | Karin Soderkvist | N/A |
| Active Not Recruiting | A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer NCT05067140 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Active Not Recruiting | Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide NCT04335682 | Alliance Foundation Trials, LLC. | Phase 2 |
| Unknown | A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA) NCT04660617 | West China Hospital | — |
| Recruiting | Dutch National Randomized Study: PSMA-PET/CT As a Triage Tool for Pelvic Lymph Node Dissection in Prostatectom NCT05000827 | Canisius-Wilhelmina Hospital | N/A |
| Unknown | Telaglenastat + Talazoparib In Prostate Cancer NCT04824937 | Massachusetts General Hospital | Phase 2 |
| Active Not Recruiting | Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer NCT04848337 | University of Michigan Rogel Cancer Center | Phase 2 |
| Withdrawn | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer NCT04781374 | Beth Israel Deaconess Medical Center | Phase 2 |
| Withdrawn | 68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer NCT04483414 | Dana Mathews | Phase 2 |
| Terminated | HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) NCT03850795 | Hinova Pharmaceuticals USA, Inc. | Phase 3 |
| Completed | An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Contin NCT05384002 | Fondazione del Piemonte per l'Oncologia | — |
| Unknown | Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer NCT04641078 | University Hospital, Ghent | Phase 2 |
| Completed | Metastatic Prostate Cancer Men's Attitudes Towards Treatment of the Local Tumour and Metastasis Evaluative Res NCT04590976 | Imperial College London | — |
| Unknown | A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC NCT04603833 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Unknown | Molecular Profiling in Prostate Cancer NCT04983628 | Hellenic Cooperative Oncology Group | — |
| Completed | PROState Pathway Embedded Comparative Trial NCT04400656 | Imperial College London | — |
| Active Not Recruiting | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors NCT04478279 | Sapience Therapeutics | Phase 1 / Phase 2 |
| Completed | The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer NCT04179968 | Dana Mathews | Phase 2 |
| Completed | Checkpoint Inhibitors and SBRT for MCRPC NCT05655715 | Herlev and Gentofte Hospital | Phase 2 |
| Active Not Recruiting | Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer NCT03784755 | Canadian Cancer Trials Group | N/A |
| Completed | MSG Use With 18F-DCFPyL PET/CT Imaging NCT03693742 | British Columbia Cancer Agency | N/A |
| Unknown | Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. NCT04116775 | Julie Graff, MD | Phase 2 |
| Recruiting | National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients NCT04086290 | Peter Busch Østergren | Phase 1 / Phase 2 |
| Active Not Recruiting | Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer NCT04030338 | Memorial Sloan Kettering Cancer Center | — |
| Completed | ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer NCT04028388 | Modra Pharmaceuticals | Phase 2 |
| Completed | A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer NCT04019327 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Nai NCT03833921 | Martha Mims | Phase 2 |
| Active Not Recruiting | REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer NCT03951831 | Mark Stein | Phase 2 |
| Completed | Safety and Pharmacokinetics of ODM-209 NCT03878823 | Orion Corporation, Orion Pharma | Phase 1 / Phase 2 |
| Terminated | A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer NCT03843918 | Laekna Limited | Phase 1 / Phase 2 |
| Unknown | Testing Radical Prostatectomy in Chinese Men With Prostate Cancer and oligoMetastases to the Bone NCT03988686 | Fudan University | N/A |
| Completed | Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer NCT03888612 | Arvinas Inc. | Phase 1 / Phase 2 |
| Unknown | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metas NCT03775525 | Genzada Pharmaceuticals USA, Inc. | Phase 1 |
| Completed | Exercise for Advanced Prostate Cancer: a Multicomponent Feasibility Trial NCT03658486 | Queen's University, Belfast | N/A |
| Completed | A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) NCT03575819 | Fortis Therapeutics, Inc. | Phase 1 |
| Completed | The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients NCT04776889 | National Cancer Institute, Egypt | Phase 4 |
| Completed | MGD019 DART® Protein in Unresectable/Metastatic Cancer NCT03761017 | MacroGenics | Phase 1 |
| Completed | Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer NCT03739684 | Progenics Pharmaceuticals, Inc. | Phase 3 |
| Completed | Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer NCT03646162 | Veru Inc. | Phase 2 |
| Completed | Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair NCT03413995 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Unknown | Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate NCT05078151 | Vall d'Hebron Institute of Oncology | N/A |
| Completed | Cytoreductive Prostatectomy Versus Cytoreductive Prostate Irradiation As a Local Treatment Option for Metastat NCT03655886 | University Hospital, Ghent | Phase 2 |
| Active Not Recruiting | A Trial of Ipatasertib in Combination With Atezolizumab NCT03673787 | Institute of Cancer Research, United Kingdom | Phase 1 / Phase 2 |
| Unknown | Selective Treatment According to Molecular Subtype of Prostate Cancer NCT03696186 | Tianjin Medical University Second Hospital | Phase 2 |
| Withdrawn | Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC NCT03494803 | HKGepitherapeutics | — |
| Completed | 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa) NCT03490032 | Advanced Accelerator Applications | Phase 1 / Phase 2 |
| Active Not Recruiting | PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases NCT03569241 | University Hospital, Ghent | Phase 2 |
| Active Not Recruiting | Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer NCT03436485 | Orion Corporation, Orion Pharma | Phase 1 / Phase 2 |
| Completed | Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence NCT03396874 | University of Michigan | Phase 2 |
| Completed | Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMA NCT03434158 | Spanish Oncology Genito-Urinary Group | Phase 2 |
| Unknown | A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Mi NCT03129139 | Minneamrita Therapeutics LLC | Phase 1 |
| Completed | Ga-68-PSMA-11 in High-risk Prostate Cancer NCT03362359 | German Cancer Research Center | Phase 1 / Phase 2 |
| Unknown | Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303) NCT03414437 | Carolina Research Professionals, LLC | — |
| Unknown | Evaluation of the Metastasis and Recurrence of Prostate Cancer NCT03507595 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Completed | Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel NCT03295565 | The Netherlands Cancer Institute | Phase 2 / Phase 3 |
| Completed | Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a NCT02961257 | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | Phase 3 |
| Unknown | Expression of Molecular Markers in Circulating Tumor Cells of Metastatic Castration-Resistant Prostate Cancer NCT03089099 | Fudan University | — |
| Terminated | ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents. NCT02933801 | Swiss Cancer Institute | Phase 2 |
| Recruiting | Androgen Deprivation Therapy (ADT) Versus ADT Plus Prostate Cryotherapy for Metastatic Prostate Cancer (mPCa) NCT03129854 | Sun Yat-sen University | N/A |
| Completed | Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Sympto NCT03024216 | University of Hawaii | Phase 1 |
| Terminated | uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cance NCT02964988 | Rigshospitalet, Denmark | Phase 2 |
| Active Not Recruiting | Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC NCT02913196 | Weill Medical College of Cornell University | Phase 1 |
| Completed | Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC) NCT02825628 | DexTech Medical AB | Phase 2 |
| Unknown | Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study) NCT04833517 | Universität des Saarlandes | — |
| Completed | Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Cas NCT02485691 | Sanofi | Phase 4 |
| Completed | Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223 NCT03223727 | The Netherlands Cancer Institute | — |
| Completed | Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enz NCT02815033 | The European Uro-Oncology Group | Phase 2 |
| Terminated | Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Cas NCT02379390 | Sanofi | Phase 2 |
| Completed | A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer NCT02407054 | Eli Lilly and Company | Phase 2 |
| Completed | PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide NCT02814968 | The European Uro-Oncology Group | Phase 2 |
| Completed | Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With R NCT03223597 | The Netherlands Cancer Institute | — |
| Terminated | A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC NCT02378870 | DexTech Medical AB | Phase 2 |
| Completed | Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer NCT02074137 | Sanofi | Phase 4 |
| Completed | Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Explori NCT01718353 | Sanofi | Phase 2 |
| Completed | Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prosta NCT02105675 | SOTIO a.s. | Phase 2 |
| Terminated | Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone NCT01428219 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC) NCT01595087 | DexTech Medical AB | Phase 1 / Phase 2 |
| Completed | Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prost NCT01487863 | Dendreon | Phase 2 |
| Completed | A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Mini NCT01322490 | Bavarian Nordic | Phase 3 |
| Completed | EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer NCT01360840 | EMD Serono | Phase 2 |
| Completed | Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated NCT01254279 | Sanofi | Phase 3 |
| No Longer Available | Clinical Use of 68Ga PSMA-11 PET/CT in Diagnosing, Staging and Restaging Prostate Cancer NCT05002465 | Dana Mathews | — |
| Approved For Marketing | Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer NCT04452136 | Jeanne Link | — |